StreetInsider.com News Articles

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Deardorf Caren

Mon, 22 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260622/26674057.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Deardorf Caren

Mon, 22 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260622/26674057.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Fust Matthew K

Mon, 22 Jun 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260622/26674020.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Fust Matthew K

Mon, 22 Jun 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260622/26674020.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Nichols Weston

Mon, 22 Jun 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260622/26674013.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Nichols Weston

Mon, 22 Jun 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260622/26674013.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Vivaldi Coelho Rogerio

Mon, 22 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260622/26674003.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Vivaldi Coelho Rogerio

Mon, 22 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260622/26674003.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Bedrosian Camille L

Mon, 22 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260622/26673992.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Bedrosian Camille L

Mon, 22 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260622/26673992.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: WIERENGA WENDELL

Mon, 22 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260622/26673985.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: WIERENGA WENDELL

Mon, 22 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260622/26673985.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Okey Stephanie

Mon, 22 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260622/26673954.html

Form 4 Crinetics Pharmaceutical For: Jun 18 Filed by: Okey Stephanie

Mon, 22 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260622/26673954.html

Form 8-K Crinetics Pharmaceutical For: Jun 18

Mon, 22 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260622/26673335.html

Form 8-K Crinetics Pharmaceutical For: Jun 18

Mon, 22 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260622/26673335.html

Stifel Reiterates Buy Rating on Crinetics (CRNX)

Mon, 22 Jun 2026 09:34:54 -0400

Stifel analyst Alex Thompson reiterated a Buy rating and $83.00 price target on Crinetics (NASDAQ: CRNX).

The analyst commented, " We sat down with Crinetics CFO Toby Schilke and Director of IR Michelle Greenblatt to discuss the Palsonify launch in Acromegaly, development in Carcinoid Syndrome, and the ongoing Atumelnant Ph3 CAH study as well as the broader pipeline. On Palsonify, CRNX remains encouraged with launch progress to date and expects continued steady uptake across new enrollments which has been predominantly switch patients (~70%) across a mix of academic and community centers. Beyond acromegaly, there is further opportunity in Carcinoid where similar

Form 4 Crinetics Pharmaceutical For: Jun 17 Filed by: Okey Stephanie

Thu, 18 Jun 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260618/26667346.html

Form 4 Crinetics Pharmaceutical For: Jun 17 Filed by: Okey Stephanie

Thu, 18 Jun 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260618/26667346.html

Form 144 Crinetics Pharmaceutical Filed by: Okey Stephanie

Wed, 17 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260617/26660298.html

Form 144 Crinetics Pharmaceutical Filed by: Okey Stephanie

Wed, 17 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260617/26660298.html

Crinetics (CRNX) Reiterated at Market Outperform by Citizens on ENDO Updates

Tue, 16 Jun 2026 05:12:35 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $95.00 price target on Crinetics (NASDAQ: CRNX).

The analyst commented, "CRNX took center stage at ENDO, with updates providing further support of Palsonify during its early launch phase in acromegaly, as well as updates for atumelnant in both CAH and Cushing’s. Palsonify continues to reinforce its best in class efficacy profile with durable ~twoyear OLE data validating it as a compelling alternative to long-acting injectable SSAs. Early launch dynamics remain highly encouraging, with ~$10M in 1Q sales (doubling Q/Q) and a steadily expanding prescriber base, supporting our view that the once-daily

H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)

Mon, 15 Jun 2026 06:48:04 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $81.00 price target on Crinetics (NASDAQ: CRNX).

The analyst commented: "Crinetics presented new long-term follow-up data from the PATHFNDR-1 and PATHFNDR-2 OLE studies at ENDO 2026, further supporting the durability of Palsonify's efficacy and safety profile. In PATHFNDR-1, which enrolled patients previously controlled on injectable SRLs, with baseline mean IGF-1 levels at 0.91x ULN at enrollment in OLE, their IGF-1 levels remained stable up to 96 weeks at 0.81x ULN. Pituitary tumor volumes remained stable in all patients at week 48 relative to the OLE baseline. PATHFNDR-2 enrolled adults with biochemically

Crinetics reports two-year PALSONIFY acromegaly treatment data

Mon, 15 Jun 2026 03:02:51 -0400

Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) presented long-term clinical data for its acromegaly treatment PALSONIFY at the Endocrine Society's Annual Meeting on June 14. The data covered up to two years of treatment from open-label extension studies of the PATHFNDR-1 and PATHFNDR-2 trials.

In the PATHFNDR-1 extension study, 53 patients who had switched from monthly injectable treatments maintained stable IGF-1 levels over 96 weeks. Baseline IGF-1 levels of 0.91 times the upper limit of normal remained at 0.81 times the upper limit at 96 weeks. All patients showed stable pituitary tumor volumes at 48 weeks.

The PATHFNDR-2 extension study included 114 patients with

Crinetics reports two-year PALSONIFY acromegaly treatment data

Mon, 15 Jun 2026 03:02:51 -0400

The PATHFNDR-2 extension study included 114 patients with